Advertisement

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement

Aug

16

Today In Oncology

What Is the Optimal PSA to Determine Prostate Cancer Treatment Efficacy

Can Newborn Genetic Testing Identify Cancer Predisposition Genes

FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma

Cretostimogene Grenadenorepvec in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

QOL Impact of Postmastectomy Chest Wall Radiotherapy 5-Year Follow-up

Advertisement

© 2026 HSP News Service, L.L.C.